Darwin Biosciences

All COVID-19 diagnostics currently being used detect biomolecules indicating infection after it’s too late, but Darwin Biosciences has developed SickStick, a diagnostic test that knows you’re sick before you do. The company offers two saliva-based solutions, one ready now for confirmatory testing that’s lab based (CoVScreen), and one requiring additional resources to accelerate its development (CoVStick). The company is in need of resources for aggressive acceleration of product release:

• COVID-19 samples in any biospecimen form — enables confirmatory testing within days
• Clinical trial site(s) to execute protocol and determine sensitivity and specificity
• Capital and partners to achieve our six month goals

Contact CEO Nick Meyerson at nrmeyerson@gmail.com and COO Rick Whitcomb at rick@rickwhitcomb.com for SickStick inquiries.

Check Out This Story

BCell Solutions, Inc.

BCell Solutions, Inc., a pre-clinical stage biopharmaceutical company, is assessing use of its peptide immunotherapies as a potential therapeutic intervention to assist late-stage, critically ill COVID-19 patients. It’s BCS-N01 immunotherapy appears effective in blockading pro-inflammatory cytokines IL-1B and IL-6, which appear centrally involved in lethal hyper-inflammation (such as virus-induced sepsis) associated with end stage organ failure in COVID-19 patients. The company is seeking industry collaboration and funding to support their COVID efforts. 

Contact CEO Chip Landman at cl@watersolve.com for B Cell related inquiries.

VitriVax

VitriVax has developed a vaccine formulation platform that enables thermostability, extended shelf life, and combined doses in a single injection, for virtually any vaccine. The company is currently working on a pilot-scale system capable of producing 10,000 to 100,000 doses of COVID-19 vaccines per run that would be ready for use as human trials of vaccines begin in the next year. The company is looking for investment, grant funding, and partners with COVID vaccine candidates that could benefit from thermostability and combining prime and boost doses into a single injection.

Contact CEO Matt Raider at mraider@vitrivaxbio.com for VitriVax related inquiries.

Check Out This Story

New Iridium

New Iridium, a company developing commercialized photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $256,000 to conduct research and development work on facilitating timely availability of Remdesivir, a potential life-saving drug in the global fight against COVID-19. This grant funds the development of an optimized manufacturing process for Remdesivir that utilizes photocatalysis, a powerful new chemical technology driven by light rather than heat. If successful, the new process will result in shortened production times and higher yields, providing greater supply to the market more quickly than current manufacturing protocols. 

Contact CEO and founder Chern-Hooi Lim at chern@newiridium.com for New Iridium related inquiries.

Read the Press Release